Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | OAT | P04181 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620727 | 1.00 | BTK (0.41) | BTKANPEPTSHRSLC6A1SLC6A11 | |
| SCHEMBL25250387 | 1.00 | BTK (0.41) | BTKANPEPTSHRSLC6A1SLC6A11 | |
| SCHEMBL28493088 | 0.87 | ACE (0.39) | BTKTSHRSLC6A1SLC6A11LMNA | |
| SCHEMBL4024160 | 0.83 | MITF (0.33) | MITFCES2CES1 | |
| SCHEMBL27932295 | 0.82 | BTK (0.37) | BTK | |
| SCHEMBL3126066 | 0.82 | KDM4E (0.38) | MITFCES2CES1 | |
| SCHEMBL30726182 | 0.82 | KDM4E (0.38) | MITFCES2CES1 | |
| SCHEMBL15541922 | 0.82 | KDM4E (0.38) | MITFCES2CES1 | |
| Hydrochloric Acid SCHEMBL15542195 | 0.80 | KDM4E (0.37) | MITF | |
| SCHEMBL23358995 | 0.80 | OAT (0.38) | TSHRLMNAGABRR1OATGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270216-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2025-08-28 | — | — | US | disclosed |
| EP-4514801-A1 | ANTI-INFECTIVE AGENTS | University Of Dundee (GB) | 2025-03-05 | — | — | EP | disclosed |
| CN-119212998-A | Anti-infective agents | 邓迪大学 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023209336-A1 | ANTI-INFECTIVE AGENTS | UNIVERSITY OF DUNDEE (GB) | 2023-11-02 | — | — | WO | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-20220026805-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-1399439-B1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1397363-B1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | BAYER HEALTHCARE AG (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1399439-A1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | Bayer HealthCare AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098873-A1 | 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-4970328-A | MITICIDE, FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | disclosed |
| US-4929642-A | MITICIDES, FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-05-29 | — | — | US | disclosed |
| EP-0300218-A1 | Use of substituted 1,4-naphthoquinones against nites and fungi | BAYER AG (DE) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254187-A1 | 5-ethyl-imidazotriazinones | EPX, TPMT, IL5 | BTK 1293/4885ANPEP 1319/4885TSHR 2163/4885 |
| US-20250270216-A1 | ANTI-INFECTIVE AGENTS | ABCB11, TUBA3C, CLPP | BTK 2114/4885ANPEP 1515/4885TSHR 4571/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | BTK 2234/4885ANPEP 3416/4885TSHR 3980/4885 |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | BTK 1207/4885ANPEP 334/4885TSHR 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.